Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
55 pending office actions • 37 clients • 54 examiners • 39 art units • 0 of 55 (0%) have an AI response strategy ready
Umberg Zipser, LLP has handled 1847 career applications, with a focus on the Biotechnology & Pharmaceuticals technology area. The firm has achieved a resolved allowance rate of 80.77 percent across its historical portfolio. This volume of applications reflects the firm's experience with the examination challenges found in the life sciences sector.
The firm averages 3.27 office actions per allowance, which indicates a prosecution cycle involving multiple exchanges with the patent office. Currently, there are 40 pending office actions that the firm is managing. This active caseload requires responses to address examiner rejections and move applications toward grant.
The 1847 career applications and the 80.77 percent allowance rate provide a data-grounded view of the firm's performance. Practitioners can use the 3.27 office actions per allowance to set expectations for the timeline of new filings within this technical domain. These metrics offer a view of the firm's historical activity and current workload.
Based on the USPTO statutory response window for each pending office action. 19 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 19 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 13 (24%) |
| §103 only | 16 (29%) |
| §102 only | 2 (4%) |
| §112 only | 2 (4%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 4 (7%) |
| Multi-statute (no §101) | 15 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, MARY K | 2 | 59.0% | +34.0% |
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| HANSEN, JARED A | 1 | 54.1% | +48.6% |
| SANG, HONG | 1 | 55.0% | +62.4% |
| PAULS, JOHN A | 1 | 49.1% | +27.4% |
| ARANT, HARRY E | 1 | 49.6% | +21.4% |
| TRIEU, VAN THANH | 1 | 84.5% | +13.8% |
| PUTTAIAH, ASHA | 1 | 21.2% | +21.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18988649 | System and Methods for Theft Prevention of a Vehicle Component | TRIEU, VAN THANH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280778 | Multi-Dose Container for Ophthalmic Compositions | FAY, ZOHREH ALEMZADEH | 119d overdue |
| 18292702 | Method And Device For Detecting Multi-Access Account By Using Similarity Degree Between Nicknames | RENWICK, REGINALD A | 31d overdue |
| 18876659 | Improvements In Or Relating To Data Integrity | PUTTAIAH, ASHA | 25d overdue |
| 18589965 | Stackable Tower with Hollow Pieces | DAVISON, LAURA L | 3d overdue |
| 18782979 | Arthroscopic Surgery System And Method | LABRANCHE, BROOKE N | 1d overdue |
| 17850756 | METHODS FOR FORECASTING CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA USING RNA-BASED BIOMARKERS AND MACHINE LEARNING ALGORITHMS | SMITH, JENNIFER JOY | 9d |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 16d |
| 19047205 | Compositions and Methods to Form a Thermally Conductive Sheath | ARANT, HARRY E | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16222798 | Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations | ZEMAN, MARY K | 77d overdue |
| 18876659 | Improvements In Or Relating To Data Integrity | PUTTAIAH, ASHA | 25d overdue |
| 19047205 | Compositions and Methods to Form a Thermally Conductive Sheath | ARANT, HARRY E | 34d |
| 19460222 | STABLE COMPOSITIONS OF BUPIVACAINE HYDROCHLORIDE | ELENISTE, PIERRE PAUL | — |
| 19454185 | haNK Cetuximab Combinations And Methods | GODDARD, LAURA B | — |
| 19447763 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | DUFFY, BRADLEY | — |
| 19411048 | Prismatic Battery Cell and Method of Making the Same | HANSEN, JARED A | — |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1675 | 2 |
| 1685 | 2 |
| 1686 | 2 |
| 1622 | 1 |
| 1643 | 1 |
| 1723 | 1 |
| 1646 | 1 |
| 3683 | 1 |
| 3763 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19460222 | STABLE COMPOSITIONS OF BUPIVACAINE HYDROCHLORIDE | Nevakar Injectables Inc. | ELENISTE, PIERRE PAUL | 1622 | §103 | Final Rejection | — | Pending | Jan 26, 2026 |
| 19454185 | haNK Cetuximab Combinations And Methods | Nantcell, Inc. | GODDARD, LAURA B | 1642 | DP | Final Rejection | — | Pending | Jan 20, 2026 |
| 19447763 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | Albunext, LLC | DUFFY, BRADLEY | 1643 | DP | Non-Final OA | — | Pending | Jan 13, 2026 |
| 19411048 | Prismatic Battery Cell and Method of Making the Same | Nantg Power, LLC | HANSEN, JARED A | 1723 | §103 | Final Rejection | — | Pending | Dec 05, 2025 |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | Immunitybio, Inc. | SANG, HONG | 1646 | §102§112 | Final Rejection | — | Pending | Nov 24, 2025 |
| 19288633 | Systems and Methods for Detecting and Documenting Cryogenic Therapy of a Patient | Katherine Bao-Shian Lee Md, Apc | PAULS, JOHN A | 3683 | §101§103 | Non-Final OA | — | Pending | Aug 01, 2025 |
| 19047205 | Compositions and Methods to Form a Thermally Conductive Sheath | Xgs Energy, Inc. | ARANT, HARRY E | 3763 | §102§103 | Final Rejection | 34d | Pending | Feb 06, 2025 |
| 18988649 | System and Methods for Theft Prevention of a Vehicle Component | Catrak Technologies, Inc. | TRIEU, VAN THANH | 2685 | §103 | Final Rejection | — | Pending | Dec 19, 2024 |
| 18876659 | Improvements In Or Relating To Data Integrity | Tokencertify Limited | PUTTAIAH, ASHA | 3691 | §101§103 | Final Rejection | 25d overdue | Pending | Dec 18, 2024 |
| 18868726 | Surgical Assembly and System | Alesi Surgical Limited | OUYANG, BO | §103 | Non-Final OA | — | Pending | Nov 22, 2024 | |
| 18882219 | Nant COVID Vaccine Cross Reactivity | Immunitybio, Inc. | WANG, RUIXUE | §102§103§112Other | Non-Final OA | — | Pending | Sep 11, 2024 | |
| 18820045 | Methods And Systems For Producing Carbon-Neutral Fuels From Aragonite | Calcean Minerals And Materials, LLC | JEONG, YOUNGSUL | §112Other | Non-Final OA | — | Pending | Aug 29, 2024 | |
| 18782979 | Arthroscopic Surgery System And Method | Convergence Medical Pty Ltd. | LABRANCHE, BROOKE N | 3771 | §102§103§112 | Final Rejection | 1d overdue | Pending | Jul 24, 2024 |
| 18715883 | UV SYSTEM AND METHODS FOR GENERATING AN ALPHA CHANNEL | The Invisible Pixel Inc. | BOYLAN, JAMES T | 2486 | §103 | Non-Final OA | 15d overdue | Pending | Jun 03, 2024 |
| 18671662 | Primary T-Cell Expansion | Nantbio, Inc. | BELYAVSKYI, MICHAIL A | §103 | Non-Final OA | — | Pending | May 22, 2024 | |
| 18643905 | Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment | Nantbio, Inc. | WOOLWINE, SAMUEL C | §103 | Non-Final OA | — | Pending | Apr 23, 2024 | |
| 18614525 | OPTICAL DISPLAY DEVICE | Innerscene Limited | OSINSKI, MICHAEL S | 2674 | §102§103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | Nant Holdings Ip, LLC | ATKINSON, JOSHUA ALEXANDER | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18693129 | COMPOSITION AND COMPOSITE ARTICLE FOR FORMING NITRIC OXIDE | Sterile State, Inc. | CHEN, CHANGRU | 1796 | §102§103 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18606693 | BIO-RESORBABLE ORTHOPAEDIC LAG SCREW FOR SMALL BONE FRACTURE FIXATION | Biocomposites Limited | COLEY, ZADE JAMES | 3775 | §102§103 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18594178 | Chlorthalidone Compositions And Methods | Nivagen Pharmaceuticals, Inc. | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Non-Final OA | 40d | Pending | Mar 04, 2024 |
| 18589965 | Stackable Tower with Hollow Pieces | UT Brands LLC | DAVISON, LAURA L | 3993 | §101§102§103§112 | Non-Final OA | 3d overdue | Pending | Feb 28, 2024 |
| 18292864 | Method And Device For User Information Prediction Using Play Log | Kakao Games Corp. | WASAFF, JOHN S. | §101§102§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 | |
| 18292702 | Method And Device For Detecting Multi-Access Account By Using Similarity Degree Between Nicknames | Kakao Games Corp. | RENWICK, REGINALD A | 3715 | §101 | Final Rejection | 31d overdue | Pending | Jan 26, 2024 |
| 18573680 | Method For Providing Dart Game And Dart Game Server | Phoenixdarts Co., Ltd. | VANDERVEEN, JEFFREY S | 3711 | §103 | Final Rejection | 15d | Pending | Dec 22, 2023 |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | Immunitybio, Inc. | PETRASH, HILARY ANN | §102§103§112 | Non-Final OA | — | Pending | Nov 15, 2023 | |
| 18555493 | Organic Compound And Organic Light Emitting Device Including Same | P&H Tech Co., Ltd. | MOWLA, GOLAM | §102 | Non-Final OA | — | Pending | Oct 13, 2023 | |
| 18474797 | Cancer Score for Assessment and Response Prediction from Biological Fluids | Nantomics LLC | LIU, GUOZHEN | §101§103§112Other | Non-Final OA | — | Pending | Sep 26, 2023 | |
| 18280778 | Multi-Dose Container for Ophthalmic Compositions | Vyluma Inc. | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Non-Final OA | 119d overdue | Pending | Sep 07, 2023 |
| 18278955 | AGRICULTURAL COMPOSITION FOR ENHANCED SILICON UPTAKE AND DISTRIBUTION IN PLANTS | Levity Crop Science Ltd. | SCHLIENTZ, NATHAN W | 1616 | §103§112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18278797 | Highly Potent M-CENK Cells And Methods | Immunitybio, Inc. | BENAVIDES, JENNIFER ANN | 1675 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18450643 | Method, Computer Program, And Device For Generating Training Dataset To Identify Hit Location Of Dart Pin | Phoenixdarts Co., Ltd. | NGUYEN, LEON VIET Q | 2663 | §103 | Non-Final OA | 3d overdue | Pending | Aug 16, 2023 |
| 18272533 | Devices and Methods for Providing Nitric Oxide | Sterile State LLC | TAI, XIUYU | §102§112 | Non-Final OA | — | Pending | Jul 14, 2023 | |
| 18272541 | Devices and Methods for Detecting the Presence of Nitric Oxide | Sterile State LLC | EOM, ROBERT J | 1797 | §102 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18343065 | Method For Change Detection | Si Analytics Co., Ltd. | LEE, BENEDICT E | 2665 | §103 | Final Rejection | — | Pending | Jun 28, 2023 |
| 18256597 | Organic Compound And Organic Light-Emitting Device Comprising Same | P&H Tech Co., Ltd. | FORTWENGLER, JAMES RICHARD | §102§103 | Non-Final OA | — | Pending | Jun 08, 2023 | |
| 18038934 | Optical Device Having Monolithic Architecture And Method For Manufacturing Same | Deep-In-Sight Co., Ltd. | BAGHDASARYAN, HOVHANNES | 3645 | §103 | Final Rejection | 16d overdue | Pending | May 25, 2023 |
| 18248855 | New Drug Prediction Method, And Apparatus For Performing Method | Deargen Inc. | LUO, JAMMY NMN | §101§103 | Non-Final OA | — | Pending | Apr 12, 2023 | |
| 18043276 | Genetic Construct | Instituto De Medicina Molecular João Lobo Antunes | MCCORMICK, CATHERINE LYNN | 1638 | §102§103 | Final Rejection | 40d | Pending | Feb 27, 2023 |
| 18021784 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | 55d | Pending | Feb 16, 2023 |
| 18164423 | Gate Operator with Context Sensitive QR Code | Intelligent Entry Machines LLC | PAN, YONGJIA | 2118 | §103 | Final Rejection | — | Pending | Feb 03, 2023 |
| 17922678 | PROCESSING 1H-NMR SPECTRAL DATA | Imperial College Innovations Limited | LEE, BYUNG RO | 2858 | §101§103 | Non-Final OA | 34d | Pending | Nov 01, 2022 |
| 17850756 | METHODS FOR FORECASTING CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA USING RNA-BASED BIOMARKERS AND MACHINE LEARNING ALGORITHMS | Genomic Testing Cooperative, Lca | SMITH, JENNIFER JOY | 1685 | §101§103§112 | Final Rejection | 9d | Pending | Jun 27, 2022 |
| 17739792 | Systems, Methods, and Compositions for Viral-Associated Tumors | Five3 Genomics, LLC | ZEMAN, MARY K | 1686 | §101§102Other | Non-Final OA | — | Pending | May 09, 2022 |
| 17740040 | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | Nant Holdings Ip, LLC | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112DP | Non-Final OA | — | Pending | May 09, 2022 |
| 17720624 | Compositions and Methods for Targeted NGS Sequencing of cfRNA and cfTNA | Genomic Testing Cooperative, Lca | POHNERT, STEVEN C | 1683 | §101§103§112 | Final Rejection | — | Pending | Apr 14, 2022 |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | Immunitybio, Inc. | LIN, JERRY | 1685 | §101§103 | Final Rejection | 16d | Pending | Apr 08, 2022 |
| 17697781 | Techniques For Performing Subject Word Classification Of Document Data | Tmaxtibero Co., Ltd. | OPSASNICK, MICHAEL N | 2658 | §102§103 | Non-Final OA | 72d | Pending | Mar 17, 2022 |
| 17631844 | Metal Recovery From Lead Containing Electrolytes | Aqua Metals Inc. | WILKINS III, HARRY D | 1794 | §103 | Final Rejection | — | Pending | Jan 31, 2022 |
| 17630075 | ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS | Immunitybio, Inc. | LU, CHENG | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 25, 2022 |
| 17270361 | Neural Interface | University Of Maribor | PORTILLO, JAIRO H | 3791 | §103 | Non-Final OA | — | Pending | Feb 22, 2021 |
| 16961026 | Fusion Protein Extensions | Nantbio, Inc. | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 5d | Pending | Oct 15, 2020 |
| 16718023 | Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity | Juvn3 Holdings, LLC | LEE, SIN J | 1613 | §103DP | Final Rejection | — | Pending | Dec 17, 2019 |
| 16576415 | SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS | Immunitybio, Inc. | FONTAINHAS, AURORA M | 1675 | §101§112 | Non-Final OA | — | Pending | Sep 19, 2019 |
| 16222798 | Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations | Five3 Genomics, LLC | ZEMAN, MARY K | 1686 | §112Other | Non-Final OA | 77d overdue | Pending | Dec 17, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial